10 Best Performing Weight Loss Companies And Their Programs

Page 3 of 11

9. Orexigen Therapeutics, Inc. (NASDAQ:OREX)

1-Year Returns: -39.64%

Orexigen Therapeutics, Inc. (NASDAQ:OREX) is another biopharmaceutical company focused on thinning out obesity. The company’s Contrave (Mysimba in Europe), which is a combination of naltrexone HCI and bupropion HCl, is a prescription treatment for obese adults. While shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) are down by nearly 40% over the past year, they’re off to a roaring start in 2017, gaining over 143%. The company provided a business update for the year at the beginning of January, and has launched a direct-to-consumer ad campaign shedding light on the connection between the brain and hunger/food cravings, and how Contrave can help quell them.

Follow Orexigen Therapeutics Inc. (NASDAQ:OREXQ)

Page 3 of 11